drugset / Trial / NCT03569995
[CREMA]Combination of R-M Followed by R-A in Elderly Patients With Primary CNS Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study was conducted to evaluate the 2-year progression free survival rate of elderly patients with primary CNS lymphoma followed by combination of rituximab and methotrexate followed by rituximab and cytarabine.
Timeline
- Start
- 2018-11-30
- Primary completion
- 2024-06
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 3000 mg/m2 | Intravenous |
| Subject | Methotrexate | Small molecule | 500 mg/m2 | Intravenous |
| Subject | Methotrexate | Small molecule | 3000 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 500 mg/m2 | Intravenous |